2016

Rampling, R. et al. (2016) A Cancer Research UK first time in human phase I trial of IMA950 (novel multi peptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clinical Cancer Research, 22(19), pp. 4776-4785. (doi: 10.1158/1078-0432.CCR-16-0506) (PMID:27225692) (PMCID:PMC5026298)

2014

Rampling, R. and Erridge, S. (2014) Management of central nervous system tumours in the elderly. Clinical Oncology, 26(7), pp. 431-437. (doi: 10.1016/j.clon.2014.03.009)

2012

Sanghera, P., Rampling, R., Haylock, B., Jefferies, S., McBain, C., Rees, J.H., Soh, C. and Whittle, I.R. (2012) The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas. Clinical Oncology, 24(3), pp. 216-227. (doi: 10.1016/j.clon.2011.06.004)

Gorlia, T. et al. (2012) New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. European Journal of Cancer, 48(8), pp. 1176-1184. (doi: 10.1016/j.ejca.2012.02.004)

Rampling, R., Sanson, M., Gorlia, T., Lacombe, D., Lai, C., Gharib, M., Taal, W., Stoffregen, C., Decker, R. and van den Bent, M.J. (2012) A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro-Oncology, 14(3), pp. 344-350. (doi: 10.1093/neuonc/nor221)

Tho, L.M., Libertini, S., Rampling, R., Sansom, O. and Gillespie, D.A. (2012) Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis. Oncogene, 31(11), pp. 1366-1375. (doi: 10.1038/onc.2011.326)

2010

Brada, M. et al. (2010) Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma. Journal of Clinical Oncology, 28(30), pp. 4601-4608. (doi: 10.1200/JCO.2009.27.1932)

2008

Albertella, M. et al. (2008) Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study. Clinical Cancer Research, 14(4), pp. 1096-1104.

2006

Dempsey, M. F., Wyper, D., Owens, J., Pimlott, S. , Papanastassiou, V., Patterson, J., Hadley, D. M., Nicol, A., Rampling, R. and Brown, S.M. (2006) Assessment of I-123-FIAU imaging of herpes simplex viral gene expression in the treatment of glioma. Nuclear Medicine Communications, 27(8), pp. 611-617. (doi: 10.1097/00006231-200608000-00003) (PMID:16829761)

2005

Quigg, M., Mairs, R. , Brown, S., Harland, J., Dunn, P., Rampling, R., Livingstone, A., Wilson, L. and Boyd, M. (2005) Assessment In Vitro of a Novel Therapeutic Strategy for Glioma, Combining Herpes Simplex Virus HSV1716-mediated Oncolysis with Gene Transfer and Targeted Radiotherapy. Medicinal Chemistry, 1(5), pp. 423-429. (doi: 10.2174/1573406054864124)

2004

Baumann, M., Leer, J., Dahl, O., De Neve, W., Hunter, R., Rampling, R. and Verfaillie, C. (2004) Updated European core curriculum for radiotherapists (radiation oncologists). Recommended curriculum for the specialist training of medical practitioners in radiotherapy (radiation oncology) within Europe. Radiotherapy and Oncology, 70, pp. 107-113. (doi: 10.1016/j.radonc.2003.12.004)

Harrow, S., Papanastassiou, V., Harland, J., Mabbs, R., Petty, R., Fraser, M., Hadley, D., Patterson, J., Brown, S. and Rampling, R. (2004) HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Therapy, 11, pp. 1648-1658. (doi: 10.1038/sj.gt.3302289)

Rampling, R., James, A. and Papanastassiou, V. (2004) The present and future management of malignant brain tumours: Surgery, radiotherapy, chemotherapy. Journal of Neurology, Neurosurgery and Psychiatry, 75, pp. 24-30. (doi: 10.1136/jnnp.2004.040535)

2003

Nicoll, J., Zunarelli, E., Rampling, R., Murray, L., Papanastassiou, V. and Stewart, J. (2003) Involvement of apolipoprotein E in glioblastoma: immunohistochemistry and clinical outcome. NeuroReport, 14, pp. 1923-1926. (doi: 10.1097/01.wnr.0000092471.09492.66)

Nicoll, J., Zunarelli, E., Rampling, R., Murray, L., Papanastassiou, V. and Stewart, J. (2003) Involvement of apolipoprotein E in glioblastoma: immunohistochemistry and clinical outcome. [Miscellaneous Article]. NeuroReport, 14(15), pp. 1923-1926.

2002

Levack, P. et al. (2002) Don't wait for a sensory level - Listen to the symptoms: A prospective audit of the delays in diagnosis of malignant cord compression. Clinical Oncology, 14, pp. 472-480. (doi: 10.1053/clon.2002.0098)

Papanastassiou, V., Rampling, R., Fraser, M., Petty, R., Hadley, D., Nicoll, J., Harland, J., Mabbs, R. and Brown, M. (2002) The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Therapy, 9, pp. 398-406. (doi: 10.1038/sj/gt/3301664)

Twelves, C. et al. (2002) Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Annals of Oncology, 13(5), pp. 777-780.

2001

Brada, M. et al. (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Annals of Oncology, 12, pp. 259-266.

1998

Barnett, S. C. , Robertson, L., Graham, D., Allan, D. and Rampling, R. (1998) Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells transformed with c-myc and H-ras form high-grade glioma after stereotactic injection into the rat brain. Carcinogenesis, 19(9), pp. 1529-1537. (doi: 10.1093/carcin/19.9.1529) (PMID:9771921)

1996

McKie, E., MacLean, A., Lewis, A., Cruickshank, G., Rampling, R., Barnett, S. , Kennedy, P. and Brown, S. (1996) Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours - evaluation of a potentially effective clinical therapy. British Journal of Cancer, 74(5), pp. 745-752. (doi: 10.1038/bjc.1996.431)

Articles

Rampling, R. et al. (2016) A Cancer Research UK first time in human phase I trial of IMA950 (novel multi peptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clinical Cancer Research, 22(19), pp. 4776-4785. (doi: 10.1158/1078-0432.CCR-16-0506) (PMID:27225692) (PMCID:PMC5026298)

Rampling, R. and Erridge, S. (2014) Management of central nervous system tumours in the elderly. Clinical Oncology, 26(7), pp. 431-437. (doi: 10.1016/j.clon.2014.03.009)

Sanghera, P., Rampling, R., Haylock, B., Jefferies, S., McBain, C., Rees, J.H., Soh, C. and Whittle, I.R. (2012) The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas. Clinical Oncology, 24(3), pp. 216-227. (doi: 10.1016/j.clon.2011.06.004)

Gorlia, T. et al. (2012) New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. European Journal of Cancer, 48(8), pp. 1176-1184. (doi: 10.1016/j.ejca.2012.02.004)

Rampling, R., Sanson, M., Gorlia, T., Lacombe, D., Lai, C., Gharib, M., Taal, W., Stoffregen, C., Decker, R. and van den Bent, M.J. (2012) A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). Neuro-Oncology, 14(3), pp. 344-350. (doi: 10.1093/neuonc/nor221)

Tho, L.M., Libertini, S., Rampling, R., Sansom, O. and Gillespie, D.A. (2012) Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis. Oncogene, 31(11), pp. 1366-1375. (doi: 10.1038/onc.2011.326)

Brada, M. et al. (2010) Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma. Journal of Clinical Oncology, 28(30), pp. 4601-4608. (doi: 10.1200/JCO.2009.27.1932)

Albertella, M. et al. (2008) Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study. Clinical Cancer Research, 14(4), pp. 1096-1104.

Dempsey, M. F., Wyper, D., Owens, J., Pimlott, S. , Papanastassiou, V., Patterson, J., Hadley, D. M., Nicol, A., Rampling, R. and Brown, S.M. (2006) Assessment of I-123-FIAU imaging of herpes simplex viral gene expression in the treatment of glioma. Nuclear Medicine Communications, 27(8), pp. 611-617. (doi: 10.1097/00006231-200608000-00003) (PMID:16829761)

Quigg, M., Mairs, R. , Brown, S., Harland, J., Dunn, P., Rampling, R., Livingstone, A., Wilson, L. and Boyd, M. (2005) Assessment In Vitro of a Novel Therapeutic Strategy for Glioma, Combining Herpes Simplex Virus HSV1716-mediated Oncolysis with Gene Transfer and Targeted Radiotherapy. Medicinal Chemistry, 1(5), pp. 423-429. (doi: 10.2174/1573406054864124)

Baumann, M., Leer, J., Dahl, O., De Neve, W., Hunter, R., Rampling, R. and Verfaillie, C. (2004) Updated European core curriculum for radiotherapists (radiation oncologists). Recommended curriculum for the specialist training of medical practitioners in radiotherapy (radiation oncology) within Europe. Radiotherapy and Oncology, 70, pp. 107-113. (doi: 10.1016/j.radonc.2003.12.004)

Harrow, S., Papanastassiou, V., Harland, J., Mabbs, R., Petty, R., Fraser, M., Hadley, D., Patterson, J., Brown, S. and Rampling, R. (2004) HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Therapy, 11, pp. 1648-1658. (doi: 10.1038/sj.gt.3302289)

Rampling, R., James, A. and Papanastassiou, V. (2004) The present and future management of malignant brain tumours: Surgery, radiotherapy, chemotherapy. Journal of Neurology, Neurosurgery and Psychiatry, 75, pp. 24-30. (doi: 10.1136/jnnp.2004.040535)

Nicoll, J., Zunarelli, E., Rampling, R., Murray, L., Papanastassiou, V. and Stewart, J. (2003) Involvement of apolipoprotein E in glioblastoma: immunohistochemistry and clinical outcome. NeuroReport, 14, pp. 1923-1926. (doi: 10.1097/01.wnr.0000092471.09492.66)

Nicoll, J., Zunarelli, E., Rampling, R., Murray, L., Papanastassiou, V. and Stewart, J. (2003) Involvement of apolipoprotein E in glioblastoma: immunohistochemistry and clinical outcome. [Miscellaneous Article]. NeuroReport, 14(15), pp. 1923-1926.

Levack, P. et al. (2002) Don't wait for a sensory level - Listen to the symptoms: A prospective audit of the delays in diagnosis of malignant cord compression. Clinical Oncology, 14, pp. 472-480. (doi: 10.1053/clon.2002.0098)

Papanastassiou, V., Rampling, R., Fraser, M., Petty, R., Hadley, D., Nicoll, J., Harland, J., Mabbs, R. and Brown, M. (2002) The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study. Gene Therapy, 9, pp. 398-406. (doi: 10.1038/sj/gt/3301664)

Twelves, C. et al. (2002) Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Annals of Oncology, 13(5), pp. 777-780.

Brada, M. et al. (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Annals of Oncology, 12, pp. 259-266.

Barnett, S. C. , Robertson, L., Graham, D., Allan, D. and Rampling, R. (1998) Oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells transformed with c-myc and H-ras form high-grade glioma after stereotactic injection into the rat brain. Carcinogenesis, 19(9), pp. 1529-1537. (doi: 10.1093/carcin/19.9.1529) (PMID:9771921)

McKie, E., MacLean, A., Lewis, A., Cruickshank, G., Rampling, R., Barnett, S. , Kennedy, P. and Brown, S. (1996) Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumours - evaluation of a potentially effective clinical therapy. British Journal of Cancer, 74(5), pp. 745-752. (doi: 10.1038/bjc.1996.431)